ArticleJournal of ginseng research2026
Ginsenoside Rb1 ameliorates endothelial dysfunction in sepsis: Targeting the RhoA/ROCK pathway to modulate mitochondrial homeostasis and inflammation.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-induced endothelial dysfunction drives organ injury through microcirculatory failure, characterized by barrier disruption and heterogeneous blood flow. Ginsenoside Rb1 (G-Rb1), a bioactive ginseng constituent, exhibits potent anti-inflammatory and antioxidant properties. This study investigates whether G-Rb1 ameliorates sepsis by preserving endothelial barrier integrity via modulating mitochondrial homeostasis and inhibiting the RhoA/ROCK pathway. Methods: A murine cecal ligation and puncture (CLP) sepsis model and lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) were employed. Endothelial barrier function, mitochondrial dynamics, and inflammatory responses were assessed via histology, flow cytometry, Western blot, and Seahorse XF analysis. RhoA/ROCK inhibitor (Fasudil) and Drp1 inhibitor (Mdivi-1) served as mechanistic controls. Results: G-Rb1 significantly improved survival in CLP mice and attenuated lung injury. It suppressed pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in bronchoalveolar lavage fluid and rebalanced T cell percentage. In HUVECs, G-Rb1 restored endothelial junction proteins (VE-cadherin, ZO-1, Claudin-5), reduced ROS/MDA, and enhanced SOD/GSH/ATP levels. Mechanistically, G-Rb1 inhibited RhoA activation and ROCK-mediated Drp1 phosphorylation (Ser616), normalizing mitochondrial fission, membrane potential, and oxidative phosphorylation. Conclusion: G-Rb1 alleviates sepsis-induced endothelial dysfunction by suppressing the RhoA/ROCK/Drp1 axis, thereby restoring mitochondrial homeostasis and barrier integrity. These findings highlight G-Rb1 as a promising therapeutic candidate for sepsis management via dual modulation of cytoskeletal dynamics and mitochondrial quality control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.